Residual and immediate effect after 16 applications of organic sources on yield and nitrogen use efficiency in black oat and corn

Soils with a long-term history of animal manure application exhibit higher residual effects of nitrogen (N) in soil and can affect the efficiency with which N will be used. This study aimed to evaluate how the immediate and residual effect of 16 applications of animal manure reflects on yields of black oat and corn rotation system, as well as N use efficiency. The study was carried out in no-tillage from 2004 to 2016 in Brazil. The treatments were pig slurry (PS), dairy slurry (DS), pig deep-litter (PL), mineral fertilizer (MF), and control (C). Prior to the sowing of black oat, in which 16 animal manure applications had already been made, an area of the soil was delimited where the treatments were not applied. This area was referred to as unfertilized (U) soil. Applications were carried out in the remaining area and were referred to as fertilized (F) soil. The highest dry matter yield and N accumulation in black oat and corn were found in F soils treated with DS and PL, respectively. In corn, the highest grain yield and N accumulation in grains were found with DS and PS. In U soil, the 16 applications (of DS especially) resulted in yields and N accumulation greater than the control and MF, but lower than those in F. The highest N use efficiency was found with DS. The history of animal manure applications was not enough to rule out additional applications in the following years

Prediction of Nitrogen Dosage in ‘Alicante Bouschet’ Vineyards with Machine Learning Models

Vineyard soils normally do not provide the amount of nitrogen (N) necessary for red wine production. Traditionally, the N concentration in leaves guides the N fertilization of vineyards to reach high grape yields and chemical composition under the ceteris paribus assumption. Moreover, the carryover effects of nutrients and carbohydrates stored by perennials such as grapevines are neglected. Where a well-documented database is assembled, machine learning (ML) methods can account for key site-specific features and carryover effects, impacting the performance of grapevines. The aim of this study was to predict, using ML tools, N management from local features to reach high berry yield and quality in ‘Alicante Bouschet’ vineyards. The 5-year (2015–2019) fertilizer trial comprised six N doses (0–20–40–60–80–100 kg N ha−1) and three regimes of irrigation. Model features included N dosage, climatic indices, foliar N application, and stem diameter of the preceding season, all of which were indices of the carryover effects. Accuracy of ML models was the highest with a yield cutoff of 14 t ha−1 and a total anthocyanin content (TAC) of 3900 mg L−1. Regression models were more accurate for total soluble solids (TSS), total titratable acidity (TTA), pH, TAC, and total phenolic content (TPC) in the marketable grape yield. The tissue N ranges differed between high marketable yield and TAC, indicating a trade-off about 24 g N kg−1 in the diagnostic leaf. The N dosage predicted varied from 0 to 40 kg N ha−1 depending on target variable, this was calculated from local features and carryover effects but excluded climatic indices. The dataset can increase in size and diversity with the collaboration of growers, which can help to cross over the numerous combinations of features found in vineyards. This research contributes to the rational use of N fertilizers, but with the guarantee that obtaining high productivity must be with adequate composition

Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19 : a meta-analysis

IMPORTANCE Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized for COVID-19 have variously reported benefit, no effect, and harm. OBJECTIVE To estimate the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes. DATA SOURCES Trials were identified through systematic searches of electronic databases between October 2020 and January 2021. Searches were not restricted by trial status or language. Additional trials were identified through contact with experts. STUDY SELECTION Eligible trials randomly assigned patients hospitalized for COVID-19 to a group in whom IL-6 antagonists were administered and to a group in whom neither IL-6 antagonists nor any other immunomodulators except corticosteroids were administered. Among 72 potentially eligible trials, 27 (37.5%) met study selection criteria. DATA EXTRACTION AND SYNTHESIS In this prospectivemeta-analysis, risk of biaswas assessed using the Cochrane Risk of Bias Assessment Tool. Inconsistency among trial results was assessed using the I-2 statistic. The primary analysis was an inverse variance-weighted fixed-effects meta-analysis of odds ratios (ORs) for 28-day all-cause mortality. MAIN OUTCOMES AND MEASURES The primary outcome measurewas all-cause mortality at 28 days after randomization. There were 9 secondary outcomes including progression to invasive mechanical ventilation or death and risk of secondary infection by 28 days. RESULTS A total of 10 930 patients (median age, 61 years [range of medians, 52-68 years]; 3560 [33%] were women) participating in 27 trials were included. By 28 days, there were 1407 deaths among 6449 patients randomized to IL-6 antagonists and 1158 deaths among 4481 patients randomized to usual care or placebo (summary OR, 0.86 [95% CI, 0.79-0.95]; P =.003 based on a fixed-effects meta-analysis). This corresponds to an absolute mortality risk of 22% for IL-6 antagonists compared with an assumed mortality risk of 25% for usual care or placebo. The corresponding summary ORs were 0.83 (95% CI, 0.74-0.92; P <.001) for tocilizumab and 1.08 (95% CI, 0.86-1.36; P =.52) for sarilumab. The summary ORs for the association with mortality compared with usual care or placebo in those receiving corticosteroids were 0.77 (95% CI, 0.68-0.87) for tocilizumab and 0.92 (95% CI, 0.61-1.38) for sarilumab. The ORs for the association with progression to invasive mechanical ventilation or death, compared with usual care or placebo, were 0.77 (95% CI, 0.70-0.85) for all IL-6 antagonists, 0.74 (95% CI, 0.66-0.82) for tocilizumab, and 1.00 (95% CI, 0.74-1.34) for sarilumab. Secondary infections by 28 days occurred in 21.9% of patients treated with IL-6 antagonists vs 17.6% of patients treated with usual care or placebo (OR accounting for trial sample sizes, 0.99; 95% CI, 0.85-1.16). CONCLUSIONS AND RELEVANCE In this prospectivemeta-analysis of clinical trials of patients hospitalized for COVID-19, administration of IL-6 antagonists, compared with usual care or placebo, was associated with lower 28-day all-cause mortality